Effectiveness and safety of IFN-free DAA HCV therapy in HIV/HCV co-infected persons: Results from a pan-European study.

Amele, Sarah; Peters, Lars; Rodger, Alison; Lundgren, Jens; Rockstroh, Jϋrgen; Matulionyte, Raimonda; Leen, Clifford; Jabłonowska, Elzbieta; Østergaard, Lars; Bhagani, Sanjay; Sarcletti, Mario; Clarke, Amanda; Falconer, Karolin; Wandeler, Gilles; Domingo, Pere; Maltez, Fernando; Zaccarelli, Mauro; Chkhartisvili, Nikoloz; Szlavik, Janos; Stephan, Christoph; ... (2021). Effectiveness and safety of IFN-free DAA HCV therapy in HIV/HCV co-infected persons: Results from a pan-European study. Journal of acquired immune deficiency syndromes, 86(2), pp. 248-257. Wolters Kluwer Health 10.1097/QAI.0000000000002541

[img]
Preview
Text
Effectiveness_and_safety_of_IFN_free_DAA_HCV.96048 (1).pdf - Published Version
Available under License Publisher holds Copyright.

Download (999kB) | Preview

OBJECTIVES

To investigate the effectiveness, safety and reasons for premature discontinuation of direct-acting antivirals (DAAs) in a diverse population of HIV/HCV co-infected individuals in Europe.

METHODS

All HIV/HCV co-infected individuals in the EuroSIDA study that started interferon (IFN) free DAA treatment between 1/6/2014 and 1/3/2018 with ≥12 weeks of follow-up after treatment stop were included in this analysis. Sustained virological response (SVR) was defined as a negative HCV-RNA result ≥12 weeks after stopping treatment (SVR12). Logistic regression was used to explore factors associated with SVR12.

RESULTS

1042 individuals started IFN-free DAA treatment after 1/6/2014 and were included, 862 (82.2%) had a known response to treatment, 789 (91.5%, 95% CI 89.7-93.4) of which achieved SVR12. There were no differences in SVR12 across regions of Europe (p=0.84). After adjustment, the odds of achieving SVR12 was lower in individuals that received sofosbuvir/simeprevir +/- RBV (aOR 0.21 (95% CI 0.08-0.53) or ombitasvir/paritaprevir/dasabuvir +/- RBV (aOR 0.46 (95% CI 0.22-1.00) compared to sofosbuvir/ledipasvir +/- RBV. 43 (4.6%) individuals had one or more components of their HCV regimen stopped early, most commonly due to toxicity (n=14); of these 14, 11 were treated with ribavirin. Increased bilirubin was the most common grade 3 or 4 laboratory adverse event (n=15.3%) and was related to treatment with atazanavir and ribavirin.

CONCLUSIONS

Our findings from real-world data on HIV/HCV co-infected individuals across Europe show DAA treatment is well tolerated, and that high rates of SVR12 can be achieved in all regions of Europe.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology

UniBE Contributor:

Wandeler, Gilles

Subjects:

600 Technology > 610 Medicine & health
300 Social sciences, sociology & anthropology > 360 Social problems & social services

ISSN:

1944-7884

Publisher:

Wolters Kluwer Health

Language:

English

Submitter:

Annelies Luginbühl

Date Deposited:

07 Dec 2020 11:34

Last Modified:

14 Jan 2021 01:32

Publisher DOI:

10.1097/QAI.0000000000002541

PubMed ID:

33079903

BORIS DOI:

10.7892/boris.147409

URI:

https://boris.unibe.ch/id/eprint/147409

Actions (login required)

Edit item Edit item
Provide Feedback